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Purpose: The aim of this study was to evaluate the long-term real-world effectiveness of
FAc and DEX implants in vitrectomized DME eyes in a real-world setting.
Methods: This was a non-interventional, retrospective, comparative study of 46 vitrecto-
mized eyes in 33 patients with persistent or recurrent DME quantified best-corrected visual
acuity (BCVA), central foveal thickness (CFT) and intraocular pressure (IOP) over up to
37 months.
Results: Both FAc and DEX treatment led to statistically and clinically significant improve-
ments in BCVA and CFT. FAc >10-letter improvement on the Early Treatment Diabetic
Retinopathy Study [ETDRS] chart over months 3–24 and a sustained ~200 µm CFT reduc-
tion over months 1–24; DEX: >5-letter improvement on the ETDRS chart at months 1 and 3
and >100 µm CFT reduction at month 1. FAc demonstrated sustained, stable and predictable
effects on BCVA and CFT over 24 months and also improved BCVA and decreased CFT in a
cohort of DME eyes that was refractory to DEX over 6 months.
Conclusion: This real-world study demonstrates long-term effectiveness of FAc in vitrec-
tomized DME eyes and sustained effectiveness in DME eyes that did not respond to DEX
therapy.
Keywords: diabetic macular edema, fluocinolone acetonide, dexamethasone implant,
intravitreal implants, real-world, vitrectomy
Background
Diabetes is a growing global health challenge. It is estimated that 424.9 million
adults were living with diabetes in 2017, and this number is expected to rise to
628.6 million by 2045.1
Approximately one-third of diabetic patients have signs of diabetic retinopathy,
out of which one-third develop vision-threatening conditions such as diabetic
macular edema (DME).2 DME presents in 14–25% of diabetics within 10 years
of the initial diabetes diagnosis.3 Factors that contribute to the increasing preva-
lence of DME include an aging population, increasing prevalence of diabetes and
longer life expectancy of patients with diabetes.4
Although there is currently no cure for DME, treatments that aim to halt or slow
down disease progression are available, and include laser therapy, intravitreal anti-
vascular endothelial growth factor (anti-VEGF) injections (ranibizumab, aflibercept
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and off-label bevacizumab) and intravitreal corticosteroid
implants (dexamethasone [DEX], fluocinolone acetonide
[FAc] and off-label injections of triamcinolone acetonide
[TA] such as the I-vation intravitreal triamcinolone acet-
onide implant.5–8 Switching between different DME ther-
apy types is common, and is often prompted by suboptimal
efficacy, adverse events, or patient or physician
preferences.9
Intravitreal corticosteroid implants that elute intravi-
treal DEX (700 µg) or FAc (190 µg) are effective for the
treatment of DME, with reduced frequencies of injection
and clinical appointments compared with anti-VEGF
therapies.6,7,10–12 ILUVIEN® (FAc) implant is a non-bio-
degradable intravitreal implant that measures approxi-
mately 3.5 mm by 0.37 mm in size. It is injected into the
vitreous using a 25-gauge injector and designed to release
0.2 µg/day of FAc over a 3-year period. In Europe it is
indicated for the treatment of vision impairment associated
with chronic DME considered insufficiently responsive to
available therapies (that is, DME that persists or recurs
despite treatment).13,14 The DEX implant is a biodegrad-
able copolymer of polylactic-co-glycolic acid that mea-
sures approximately 6 mm by 0.46 mm. It is injected
into the vitreous with a 22-gauge needle and releases
DEX for up to 6 months.
The efficacy and safety of the FAc implant in DME was
demonstrated in the FAME studies, which were conducted
under a single protocol as randomized, double-masked,
sham injection-controlled, parallel-group, multicenter stu-
dies. The main outcome, evaluated at month 36, was the
percentage of patients with an improvement in best-cor-
rected visual acuity (BCVA) of ≥15 letters, and results
showed that a significantly higher percentage of patients
achieved this after therapy with the FAc implant than with
sham control (34% versus 13%; p<0.001).6
The biodegradable intravitreal implant Ozurdex®
(DEX) is applied using a pre-loaded 22-gauge intravitreal
injector system. It contains 0.7 mg preservative-free DEX
and remains effective for up to 6 months and a recent
systematic review of real-world DEX studies indicates
the mean retreatment average time is shorter than this
and occurs around 5 months.15 The implant is indicated
for the treatment of adult patients with visual impairment
due to DME who are pseudophakic or who are considered
insufficiently responsive to, or unsuitable for, non-corti-
costeroid therapy. The effectiveness and safety of DEX in
DME was demonstrated in the pivotal MEAD study.7
Intravitreal administration of corticosteroids reduces
the risk of potential systemic side effects. The longer
treatment intervals that are associated with DEX and FAc
implants, compared with anti-VEGF therapies, also reduce
treatment costs, increase patient compliance and lower the
risk of endophthalmitis and traumatic cataract.16 These
benefits have to be balanced against a higher risk of ocular
hypertension and cataract, which are well-known and man-
ageable undesired effects of both DEX and FAc
implants.14
To the best of our knowledge, no study has so far
directly compared the effectiveness and safety of the FAc
and DEX implants for the treatment of DME. In the study
presented here, we compared the real-world effectiveness
and safety of FAc and DEX intravitreal implants in
patients with DME who have previously undergone
vitrectomy.
Methods
Aim
The primary aim of this real-world study was to investi-
gate the changes over time in BCVA, central foveal thick-
ness (CFT) and intraocular pressure (IOP) in DME
patients treated with either the FAc or DEX intravitreal
implant.
Study design
This was a non-interventional, retrospective, comparative
analysis of 46 vitrectomized eyes in 33 patients with
persistent or recurrent DME. The study was conducted at
the Centro Hospitalar Universitario do Porto, a tertiary
referral center in Oporto, Portugal. The clinical records
of patients who had received prior treatment of DME with
the FAc or DEX implant were retrieved.
Two patient groups were identified: group 1 included
29 eyes (26 patients) that had received an intravitreal
injection of the 0.2 µg/day FAc implant, while group 2
included 17 eyes (14 patients) that had received an intra-
vitreal injection of the 0.7 mg DEX implant. All patients
provided informed consent for treatment, and the study
protocol complies with the requirements of the institute’s
committee on human research.
Study endpoints
Patient demographic data were recorded, as well as the
following parameters: visual acuity which was recorded
and converted to ETDRS letters; CFT; IOP; duration of
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DME; number of intravitreal injections received; and num-
ber of topical IOP-lowering medications received.
Inclusion and exclusion criteria
The inclusion criteria were based on prior FAc and/or
DEX treatment in line with the European indications for
each drug.
Statistical analysis
The statistical analysis involved measures of descriptive
statistics (absolute and relative frequencies, averages and
respective standard deviations [SD]) and inferential statis-
tics. The level of significance to accept or reject the null
hypothesis was set at (α) ≤0.05. Student’s t-test was used
for independent samples, and Student’s t-test for paired
samples was used when comparing quantitative variables
between the baseline and each of the several moments of
observation. The assumption of normal distribution was
analysed with Shapiro–Wilk tests. When the assumptions
were not satisfied, the Mann–Whitney test was used as an
alternative to the Student t-test for independent samples
and the Wilcoxon test as an alternative to the Student’s t-
test for paired samples. The Chi-square test and the
Fischer’s test were used to test the difference between
the two proportions. Statistical analysis was performed
with SPSS (Statistical Package for the Social Sciences)
version 24.0 for Windows. Data are reported as mean ± SD
unless stated otherwise.
Results
Patient demographics
The baseline demographics of the FAc (29 eyes in 26
patients) and DEX (17 eyes in 14 patients) implant groups
are summarized in Table 1. The FAc and DEX implant
groups were well matched, with no significant differences
in participant age, duration of DME, mean number of
previous anti-VEGF injections, BCVA, CFT or IOP
(Table 1). The FAc and DEX implant groups differed
significantly in mean follow-up time (16.9 vs 5.5 months),
and both the percentage of patients receiving prior steroid
injections and the mean number of prior steroid injections
per se were higher in the FAc than the DEX implant group
(Table 1). The refractory nature of the DME study eyes
included in this study is reflected by the high treatment
burden (prior anti-VEGF and steroid treatments) at base-
line for both study groups (Table 1).
Patient disposition
This real-world study was made up of five different patient
cohorts (Figure 1) The “DEX cohort” consisted of 17 eyes
(in 14 patients) that were initially treated with DEX.
Fourteen of these eyes (in 13 patients) completed 6 months
of follow-up (the “DEX 6-month cohort”). The “FAc
cohort” included all 29 eyes (from 26 patients) that
received at least one FAc implant with a minimum fol-
low-up of 6 months. The “FAc 24 months FU cohort” was
defined as FAc cohort eyes that completed 24 months of
follow-up post FAc implantation (8 eyes in 8 patients).
Subgroup analyses were performed to compare outcomes
in the same patients. The “One DEX-to-FAc cohort” con-
sisted of 5 eyes in 5 patients with at least 12 months of
post-FAc implant follow-up that had been treated with a
single DEX implant and then switched to an FAc implant.
DEX changes in BCVA and CFTover time
In the DEX cohort, 14 eyes completed six months of
follow-up. (Figure 2A and B) Relative to the 40.6
ETDRS letter baseline, 6.5 letters were gained at month
1, 9.0 letters at month 3 and 2.8 letters at month 6.
Relative to the 470.5 µm baseline, CFT decreased by
133.1 µm at month 1, 48 µm at month 3 and 14.7 µm at
month 6.
Fac implant changes in BCVA and CFT
over time
Eight eyes from 8 patients completed 24 months of follow-
up (Figure 3A and B). Relative to the 31.5 ETDRS letter
baseline, 8.1 letters were gained at month 1, 12.9 letters at
month 3, 16.3 letters at month 6, 18.8 letters at month 12
and 18.0 letters at month 24. Relative to the 594.8 µm
baseline, CFT decreased by 201.5 µm at month 1,
206.3 µm at month 3, 195.7 µm at month 6, 240.5 µm at
month 12 and 257.0 µm at month 24.
In some cases, FAc and DEX implants were adminis-
tered to the same patients. In this subgroup, patients were
selected if they had received a single prior DEX implant
and subsequently had 12 months of follow-up after being
treated with a FAc implant. Five eyes in five patients were
initially treated with a single DEX implant before switch-
ing to the FAc implant. Relative to the 38.0 ETDRS letter
baseline, 12.5 letters were gained at month 1, and 5.0 and
1.3 letters were lost at months 3 and 6, respectively
(Figure 4A). Relative to the 499.4 µm baseline, CFT
decreased by 70.0 µm at month 1, 6.7 µm at month 3
Dovepress Coelho et al
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and increased by 59.3 µm at month 6 (Figure 4B). After a
single DEX treatment, the 5 DEX patients were switched
to an FAc implant: Following the switch to the FAc
implant, 12.6 letters were gained at month 1, 14.6 letters
Table 1 Baseline characteristics of the study participants in the FAc and DEX implant treatment groups
Baseline characteristics FAc implant (n=29 eyes
in 26 patients)
DEX implant (n=17 eyes
in 14 patients)
P-value
Age, years 68.2±8.1 68.4±9.5 NS
DME duration, years (mean ± SD) 3.9±1.8 4.6±2.1 NS
Mean number of previous anti-VEGF injections 3.4±3.4 5.5±4.4 NS
Mean number of prior steroid injections 2.7±1.4 1.4±1.1 <0.001
Mean time between vitrectomy and intravitreal implant (days) 861.9±681.4 972.5±908.4 NS
Mean BCVA, ETDRS letters 41.7±18.8 40.70±23.5 NS
Mean CFT, µm 513.7±179.0 462.0±153.3 NS
Mean IOP, mmHg 15.4±3.6 15.8±3.7 NS
Mean follow-up, months (range) 16.9±9.4 (6–37) 5.5±1.2 (3–6) <0.0001
Lens status NS
Cataract, n (%) 1 (3.4) 2 (11.8)
Phakic, n (%) 2 (6.9) 3 (17.6)
Pseudophakic, n (%) 26 (89.7) 12 (70.6
Previous IOP-lowering medication, n (%) 15 (51.7) 10 (58.8) NS
Intravitreal bevacizumab injection, n (%); 22 (75.9) 14 (82.4) NS
Mean injection number (SD) 2.5 (1.8) 4.2 (3.0)
Intravitreal ranibizumab injection, n (%); 4 (13.8) 3 (17.6) NS
Mean injection number (SD) 2.5 (1.9) 1.7 (1.2)
Intravitreal aflibercept injection, n (%); 8 (27.6) 8 (47.1) NS
Mean injection number (SD) 4.1 (1.8) 3.6 (2.1)
Intravitreal triamcinolone acetonide injection, n (%); 26 (89.7) 12 (70.6) <0.05
Mean injection number (SD) 2.5 (1.3) 1.9 (0.7)
Intravitreal dexamethasone implant injection, n (%); 11 (37.9) 0 (0.0) <0.001
Mean injection number (SD) 1.2 (0.4) 0.0 (0.0)
Notes: NS, no significant difference for FAc vs DEX implant groups. A p-value <0.05 was taken to represent a statistical difference. Comparisons were performed using a
two-tailed unpaired t-test assuming unequal variance.
Figure 1 Study design and patient disposition. In the fluocinolone acetonide (FAc) implant cohort, 11 (from 10 patients) of the 29 eyes had been treated with a prior
dexamethasone (DEX) implant. A subgroup of these (n=5 eyes from 5 patients) were assessed based on the FAc implant group having at least 12 months follow-up post-
treatment and only one DEX implant being given prior to the FAc implant.
Coelho et al Dovepress
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at month 3, 13.3 letters at month 6, 24.0 letters at month 9
and 13.0 letters at month 12 (Figure 4C). Similarly, CFT
decreased by 173.0 µm at month 1, 138.4 µm at month 3,
23.3 µm at month 6, 107.7 µm at month 9 and 114.0 µm at
month 12 following the switch from DEX to a FAc
implant (Figure 4D).
Safety and supplemental therapies
In the “FAc 24 months FU cohort” (n=8) where IOP
was 15.0±2.4 mmHg at baseline and a peak occurred
(17.0±2.8 mmHg) between weeks 2 and 4 (Table 2).
This was similar to the “DEX 6-month cohort” (n=13
of 14 with an IOP measurement at baseline) where IOP
was 16.0±4.1 mmHg at baseline and reached a maxi-
mum of 19.2±5.4 mmHg between weeks 2 and 4
(Table 2).
At their final study visit, one eye in the FAc implant
treated group and one eye in the DEX implant treated
group had IOP ≥21 mmHg, and five eyes in the FAc
implant treated group and eight eyes in the DEX implant
treated group were receiving IOP-lowering medication
(Table 2). It is notable that a similar proportion of eyes
in both groups were receiving IOP-lowering drops at base-
line (Table 2).
In the FAc implant treated patients, none of the eyes
required surgery to control IOP pressure and two eyes in
the DEX implant group had a significant increase in IOP
that required IOP-lowering treatment and subsequent sur-
gical intervention.
Post-DEX implant administration, eight eyes from the
“DEX 6-month cohort” were subsequently treated with a
FAc implant after month 6 and none received a second
DEX implant. In the FAc implant treated group, two eyes
received intravitreal injections of anti-VEGF (bevacizu-
mab and aflibercept in the first case and ranibizumab in
the second case) which started at months 9 and 21, respec-
tively. One patient was treated with panretinal photocoa-
gulation at month 15.
Figure 2 Changes in BCVA (A) and CFT (B) in 14 eyes over 6 months post DEX
implantation. n: number of unique study eyes at individual time points. The baseline
BCVA was 40.6 letters; and the baseline CFTwas 470.5 µm.
Figure 3 Effect on BCVA (A) and CFT (B) 24 months post-FAc implantation in 8 eyes that completed a 24-month follow-up. Five of the eyes had previously been treated
with a DEX implant. The baseline BCVA was 31.5 letters; and the baseline CFTwas 594.8 µm.
Dovepress Coelho et al
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Discussion
The aim of the study was to investigate the effects of FAc
and DEX intravitreal implantation in in difficult-to-treat
vitrectomized eyes with DME. Twenty-nine eyes were
treated with a FAc implant and followed for up to 37
(range: 6–37) months; 17 eyes were treated with a DEX
implant and followed for up to 6 (range: 3–6) months.
The baseline characteristics of the FAc and DEX
implant treatment groups were similar, with the exception
of mean follow-up time, mean number of prior steroid
injections, the time since vitrectomy, and number of
DEX intravitreal injections, which were all greater in the
FAc implant treatment group.
Following a single FAc implantation, treatment
resulted in a sustained increase in BCVA and sustained
reduction in CFT over up to 24 months, with only transient
increases in IOP. An adequate response from DEX implan-
tation was initially observed (BCVA gains at months 1 and
3, and a CFT decrease at month 1), but this response was
not sustained through to month 6, when both BCVA and
CFT returned to close to baseline values. Furthermore, a
subset of five DEX-treated eyes that responded inade-
quately to DEX implantation when followed over 6 months
responded well to FAc implantation, with sustained
improvements in BCVA and CFT over 12 months post-
FAc implantation. It is important to note that the small
number of study eyes at certain time points in this real-
world study of difficult-to-treat DME eyes may add noise
to the interpretation of effect of DEX and FAc implant
treatments on BCVA and CFT. Larger study cohorts of
difficult-to-treat DME eyes are needed, however, to vali-
date the findings reported in this study.
In the FAc implant treated group, CFT decreased by
approximately 200 µm in the first 12 months, which is in
line with the CFT reduction reported by a UK-based real-
world study by Alfaqawi et al,17 but almost double the
CFT reduction reported by 2 other UK based real-world
studies.18,19 Baseline CFT was slightly higher in this
study (FAc cohort: 513.7 µm; DEX cohort: 462 µm)
(Table 1), compared with other real-world FAc implant
studies (451–494 µm).17–20 which may reflect a higher
DME disease activity in our study population.
In the DEX-treated eyes that completed 6 months’
follow-up, CFT decreased by approximately 133.1 µm
at month 1, which is more than what was reported in
similar real-world studies such as REINFORCE, a large
Figure 4 Changes in BCVA (A, C) and CFT (B, D) in 5 eyes initially treated with a DEX implant (squares) and followed for 6 months (A, B) that were subsequently
switched to a FAc implant (circles) and followed for an additional 12 months post FAc implant switch (C, D). n: number of unique study eyes at individual time points. The
baseline BCVA values were as follows: a) 38.0 letters; c) 29.0 letters. The baseline CFT values were as follows: b) 499.4 µm; d) 541.0 µm.
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(n=180 eyes) US-based multicenter Phase 4 observational
study, and CHROME, a Canadian multicenter, retrospec-
tive cohort study of 120 DME eyes.21,22 The timing of the
CFT nadir in the DEX-treated group in the present study
was at 1–3 months, which is similar to the two-month
CFT nadir reported in REINFORCE.22 In contrast, in the
FAc implant treated eyes, the increase in BCVA and
decrease in CFT was sustained, stable and predictable
for up to 24 months, which aligns well with previously
reported long-term effects of the FAc implant on CFT.6
After 24 months, the number of patients treated with a
FAc implant started to decline, which prevented mean-
ingful effectiveness analyses post-24 months. Further
real-world studies with larger patient cohorts are needed
to assess outcomes after 3 years of follow-up, which is
the duration of action for which the FAc implant has been
designed.6,14
It is difficult to evaluate the effect of FAc and DEX
implants on IOP in this real-world study, as study partici-
pants in both the FAc and DEX implant cohorts were
being treated with IOP-lowering medication at baseline.
No head-to-head studies comparing the safety and effi-
cacy of FAc and DEX implants have been published to
date. This may, at least partly, be because FAc and DEX
implants have different indications for the treatment of
DME, which precludes direct comparisons of their effec-
tiveness and safety.8,14
In this real-world study, treatment with FAc and DEX
intravitreal implants led to statistically and clinically sig-
nificant improvements in both BCVA and CFT in vitrecto-
mized DME eyes. The FAc implant demonstrated
sustained, stable and predictable effects on BCVA and
CFT over 24 months. Importantly, the FAc implant also
improved BCVA and decreased CFT in a cohort of DME
eyes that displayed inadequate response to the DEX
implant over 6 months.
In conclusion, our study demonstrates long-term effec-
tiveness of the 0.2 µg/day FAc implant in vitrectomized
DME eyes in a real-world setting, as well as demonstrating
sustained effectiveness in previously treatment-refractory
vitrectomized DME eyes.
Ethics statement
Subjects (or their parents or guardians) have given their
written informed consent and the study protocol has been
approved by the research ethics committee of Centro
Hospitalar Universitário do Porto.Ta
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